Push to Limit Lower Drug Cost Program Linked to Big Pharma

The 340B Program and the Debate Over Its Use

A coalition of conservative interest groups and activists recently sent a letter to Republican congressional leaders urging them to address concerns about a program that provides discounted outpatient drugs to rural Americans. According to the letter, the 340B Drug Pricing Program is being misused by hospitals, potentially harming patients and increasing costs for everyone.

The letter claims that the program was originally designed to help hospitals provide care to low-income populations at little or no cost. However, it argues that some hospitals are exploiting the program by purchasing medicines at reduced prices and then distributing them across broader networks, including areas with higher income levels. This practice, according to the letter, leads to inflated prices for consumers.

Financial Ties Between Groups and the Pharmaceutical Industry

Many of the organizations that signed the letter have close financial ties to the pharmaceutical industry. Notably, nine of the signatories received funding from PhRMA, the primary trade organization representing drug manufacturers. These connections raise questions about the motivations behind the campaign to reform the 340B program.

For example, the Center for a Free Economy (CFE) received over $500,000 in contributions from PhRMA between 2022 and 2023, which accounted for a significant portion of its total revenue during that period. Similarly, Consumer Action for a Strong Economy received $315,000 from PhRMA between 2021 and 2023. Other groups, such as the Trade Alliance to Promote Prosperity, American Commitment, and the Competitive Enterprise Institute, also received substantial sums from the pharmaceutical industry.

Some organizations, like the 60 Plus Association and the Freedom Foundation of Minnesota, received smaller amounts—typically in the five-figure range—from the industry over the years.

Lobbying Connections and Organizational Transparency

Ryan Ellis, one of the signatories on the letter, is a lobbyist registered to work with PhRMA. He also serves as the head of the Center for a Free Economy and as a policy consultant with Akin Gump. When asked about the financial ties to PhRMA, Ellis declined to comment directly, stating that the organization does not disclose donor information due to privacy concerns.

Ellis emphasized that CFE operates based on its policy goals and only seeks funding after developing its positions. He argued that transparency about donors would undermine the organization’s credibility and effectiveness.

Balancing Priorities: Regulation vs. Access to Care

The push to reform the 340B program highlights a tension within the Republican party. On one hand, there is a long-standing focus on reducing government regulation, which many in the pharmaceutical industry argue drives up consumer prices. On the other hand, there is a commitment to ensuring affordable healthcare for rural and underserved communities.

Pharmaceutical interests cite instances of abuse, such as the case involving Bon Secours Mercy Health, which allegedly saved $276 million through the 340B program. These examples are used to justify calls for reform.

However, hospital groups counter that the program already includes strict requirements for participation. They argue that the low-cost medications provided under the 340B program are essential for delivering care to people in rural areas who may otherwise lack access to necessary treatments.

Broader Influence of the Pharmaceutical Industry

Beyond the 340B program, the pharmaceutical industry has a wide-reaching influence network. It funds lobbying efforts, media campaigns, and advocacy initiatives across the country. This influence extends into various policy areas, including Medicaid reform and tax policy.

While the letter addressed multiple issues, the primary focus remained on the 340B program and its perceived misuse. Most of the signatories did not respond to requests for additional comments, leaving many questions unanswered about their motivations and the full scope of their involvement.